GlassScriptPhysician profile
Sylvia Brown-Cates
NPI 1780289934
$1,685.09
in general payments reported to CMS, 2019-2025
23 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $324 · 2023: $449 · 2024: $356 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.36 | 2021-2025 | |
| Pfizer INC. | $174.20 | 2021-2024 | |
| Novo Nordisk INC | $166.41 | 2021-2024 | Rybelsus, Ozempic |
| Mylan Specialty L.P. | $161.51 | 2021-2024 | Yupelri |
| Lilly USA, LLC | $156.13 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Antares Pharma, INC. | $148.41 | 2024 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.76 | 2021-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.61 | 2022-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $76.46 | 2022-2024 | Rexulti |
| Bioventus LLC | $51.57 | 2023-2025 | Supartz Fx Sodium Hyaluronate, Xcell |
| Amgen INC. | $48.49 | 2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $30.54 | 2021 | |
| Gilead Sciences, INC. | $26.40 | 2024 | |
| Genentech USA, INC. | $20.06 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.47 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.05 | 2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $17.88 | 2022 | |
| Amarin Pharma, INC. | $17.80 | 2021 | |
| Allergan, INC. | $15.20 | 2021 | |
| Depuy Synthes Sales INC. | $14.99 | 2024 | Orthovisc, Monovisc |
| Exact Sciences Corporation | $14.69 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $11.85 | 2022 | |
| Athena Bioscience, LLC | $11.25 | 2024 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Brown-Cates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.